Sterile Products Community

 View Only

Open Scientific Discussion (OSD) with Chris Calderon - Recent Advances in Combining AI & Microscopy to Analyze and Monitor Biologics: Applications to Protein and Cell-Based Therapeutics

  • 1.  Open Scientific Discussion (OSD) with Chris Calderon - Recent Advances in Combining AI & Microscopy to Analyze and Monitor Biologics: Applications to Protein and Cell-Based Therapeutics

    Community Leadership
    Posted 03-13-2024 08:42

    Please join this Open Scientific Discussion (OSD) hosted by the AAPS Biopharmaceutical Product Attributes and Biological Consequences (BPABC) Community on Tuesday, 26 March 2024, 12 PM – 1 PM US EST on:  

    Recent Advances in Combining AI & Microscopy to Analyze and Monitor Biologics:  Applications to Protein and Cell-Based Therapeutics

    Speaker / Discussion Leader: Chris Calderon, Ph.D. (Ursa Analytics, Inc., Denver CO and Associate Research Professor, Univ. of Colorado, Boulder)

    Brief Description:

    The last decade has experienced explosive technological innovation in image and text analysis due in large part to developments in neural network algorithms and advances in graphics processor unit (GPU) hardware technology.  In this talk, we will focus on methods for using data-driven image analysis to analyze subvisible particles in biologic drug products. Historically, practitioners and regulators have depended on sub-optimal human-defined features (such as aspect ratio, average pixel intensity, etc.) to characterize subvisible drug particle images.  However, modern neural networks allow product specific data-driven attributes to be extracted from images characterizing biologic drug products in a high-throughput fashion. 

    This talk will discuss: 

    • new methods for characterizing biologic drugs in formulation development (providing insights into the primary mechanism of particle formation) and in process monitoring. 
    • how recent advances in supervised and unsupervised machine learning representation learning can be used to characterize cell-based medicinal products (CBMPs) in a "label-free" (i.e., stain-free and non-perturbative) fashion.

    We look forward to your participation in a lively discussion on this topic!

    When: 26th March 2024, 12 PM – 1 PM US EST

    Where: Please join Teams meeting using link provided below from your computer, tablet or smartphone.

    https://teams.microsoft.com/l/meetup-join/19%3ameeting_NTIzZGZmNjMtN2MwNy00NWQ0LWI3OWItYjcxMWU3MjE1YTA4%40thread.v2/0?context=%7b%22Tid%22%3a%22d7811cde-ecef-496c-8f91-a1786241b99c%22%2c%22Oid%22%3a%22da6f9c8c-317b-4a76-90c1-87ab430ab9a3%22%7d

    Please feel free to share meeting information with your colleagues who may be interested in this discussion.

    Thank you,

    BPABC Leadership Team



    ------------------------------
    Suman Luthra
    Director
    Merck
    Boston MA
    [email protected]

    Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
    ------------------------------